Key Takeaways for IDEXX Laboratories Stock as of July 2026
- Nine of 15 analysts rate IDEXX Laboratories stock buy or outperform against 5 holds and a single underperform, with a $708 mean target implying 25% upside from today’s $567.
- TIKR’s mid-case values IDXX at $888 by December 2030: 57% total return, 11% annualized.
- At 8% forward revenue growth, consensus prices in a steep deceleration from Q1’s 14% actual, leaving IDEXX stock undervalued if the innovation pipeline keeps volume growth above that floor.
- Q2 results on August 4 and an Investor Day on August 13, where incoming CEO Mike Erickson will detail the next innovation wave, create the near-term catalyst window for the stock.
IDEXX Posts 14% Revenue Growth as inVue Dx and Cancer Dx Fuel a Q1 Beat
IDEXX Laboratories (IDXX) reported Q1 fiscal 2026 revenue of $1.14 billion on May 5, beating the Street’s $1.11 billion estimate by 3% and capping a four-quarter run of accelerating year-over-year growth.
Behind that top-line beat, CAG Diagnostics recurring revenue, the company’s largest high-margin business, grew 11% organically, split between nearly 11% U.S. gains and 12% international growth fueled by commercial expansion and net new customer wins.
Two product cycles powered those gains. IDEXX placed 1,100 inVue Dx analyzers in Q1, tracking toward a full-year target of 5,500 units, while growing its premium instrument installed base 12%.
Cancer Dx added a separate growth vector, with over 7,500 practices now ordering the canine lymphoma screen and 20% of those accounts coming from clinics that don’t use IDEXX as their primary reference lab. CEO Jay Mazelsky framed the competitive impact on the Q1 earnings call: “Cancer Dx is a major differentiator for our Reference Lab business, and we believe it is one of the many elements driving competitive lab transitions to IDEXX.”
Beyond those two platforms, VetLab consumable revenue climbed 15% organically and Reference Lab revenue rose 10%, both reflecting the pull-through of a growing installed base and higher diagnostic frequency per visit.
Those volume gains should widen once inVue Dx’s fine needle aspirate (FNA) module moves from controlled to full-volume launch in the second half of 2026, opening a testing category where veterinarians currently examine fewer than 10% of suspicious masses.
Buoyed by that revenue acceleration, comparable operating profit climbed 15%, with gross margins expanding 90 basis points to 63.4%.
Management raised full-year revenue guidance to $4.68 to $4.76 billion and lifted EPS expectations to $14.45 to $14.90, embedding an improved clinical visit forecast of minus 1.5% after Q1 visits came in at minus 1%. The improvement traces to pandemic-era pets aging past five years, a cohort that posted positive visit growth for a third straight quarter across both well and non-well categories.
Incoming CEO Mike Erickson, a 14-year IDEXX veteran who takes the role after the May 12 annual meeting, signaled continuity at a Stifel conference on May 27: “I’ve never been more excited about our portfolio of innovations. We’re in a real cycle right now.”
Wall Street’s $708 Target Implies 25% Upside for IDEXX Stock
With 9 buy-or-outperform ratings, 5 holds, and a single underperform among 15 analysts, the Street leans bullish on IDEXX Laboratories stock. The mean of 14 price targets sits at $708, 25% above the current $567 close, with a $708 median confirming tight consensus. Targets span $470 to $805, but that narrow mean-to-median gap signals conviction rather than a split camp.
Wall Street Expects IDEXX Stock Revenue Growth to Slow to 8% Through Mid-2027
IDEXX Laboratories stock posted Q1 revenue of $1.14 billion, a 14% year-over-year gain that completed a four-quarter acceleration from 11% to 14% and outpaced every growth rate on the forward consensus curve.
The Street projects a sharp step down. Analysts model $1.20 billion for June 2026 and $1.19 billion for September, both at roughly 8% growth, cutting the Q1 pace nearly in half.
That deceleration holds through mid-2027: December 2026 sits at $1.18 billion and June 2027 reaches $1.30 billion, both near the same 8% band. Management’s raised guidance of $4.68 to $4.76 billion for fiscal 2026 implies 9% to 11% reported growth, but Street estimates for the back-half quarters lean toward the lower bound.
Whether August 4’s Q2 report breaks that 8% ceiling or confirms it will hinge on the first visible revenue contribution from expanded FNA volumes and Cancer Dx’s European and Australian launch.
TIKR Values IDEXX Stock at $888, Pricing In Sustained Diagnostic Volume Gains
TIKR’s mid-case model values IDEXX at $888 by December 2030, implying 57% total return from the current $567 price, or 11% annualized over 4.4 years.
An 11% annualized return sits well above the mid-single-digit expectation typical of large-cap healthcare, reflecting a business that has compounded revenue above 10% for a decade and shows no structural deceleration inside its largest segments.
That target prices in the same installed-base flywheel and Cancer Dx competitive pull-through visible in Q1, compounded by FNA’s upcoming full-volume launch into a testing category where 90% of addressable volume remains untapped. With the forward consensus curve modeling 8% growth against a business that just printed 14%, the model’s mid-case sits closer to what the fundamentals support than the Street’s current baseline.
Should You Invest in IDEXX Laboratories?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IDEXX Laboratories stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IDEXX Laboratories alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze IDXX stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
